Access Statistics for Aidan Hollis

Author contact details at EconPapers.

Working Paper File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
A Contractual Approach to the Gray Market 0 1 1 428 0 1 13 2,115
Complementarity, Competition and Institutional Development: The Irish Loan Funds through Three Centuries 0 0 0 295 0 1 4 1,326
Exclusivity Restrictions in Markets with Adverse Selection: The Case of Extended Warranties 0 0 0 106 0 0 8 850
Generic drug pricing in Canada: components of the value-chain 0 1 1 107 1 2 11 339
Microcredit in Pre-Famine Ireland 0 0 3 338 1 2 19 1,789
New Approaches to Rewarding Pharmaceutical Innovation 0 0 0 94 1 1 14 180
Privacy, Driving Data and Automobile Insurance: An Economic Analysis 0 0 0 0 0 1 9 291
Privacy, Driving Data and Automobile Insurance: An Economic Analysis 0 0 0 70 0 1 13 259
Subsidizing the Competition 0 0 0 134 1 2 10 692
The Evolution of A Microcredit Institution: The Irish Loan Funds, 1720 - 1920 0 0 0 324 1 2 10 1,600
Total Working Papers 0 2 5 1,896 5 13 111 9,441


Journal Article File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
A National Formulary for Canada 0 0 0 547 1 1 12 4,124
A contractual approach to the gray market 0 0 0 123 0 2 10 419
An Optional Delinked Reward System: Making Pharmaceutical Innovation Work for Everyone 0 1 2 2 2 3 15 20
Climate impact auctions: an underused tool for green subsidies in the Global South 0 0 0 0 0 1 7 8
Co-authorship and the output of academic economists 0 0 0 72 0 0 9 260
Competition policy in open economies 0 0 0 32 0 0 5 173
Der Green Impact Fund for Technology 0 0 0 3 1 1 9 24
Generic Drug Pricing and Procurement: A Policy for Alberta 0 0 0 4 0 1 7 25
Governance of electricity transmission systems 0 0 0 81 0 0 11 224
How do Brands’ “Own Generics” Affect Pharmaceutical Prices? 1 1 2 193 1 2 11 498
How will recent trade agreements that extend market protections for brand-name prescription pharmaceuticals impact expenditures and generic access in Canada? 0 1 1 3 0 1 11 26
Industrial Concentration, Output, and Trade: An Empirical Exploration 0 0 0 37 1 1 11 115
Making Sure Orphan Drugs Don’t Get Left Behind 0 0 0 3 0 1 10 30
Microcredit in Prefamine Ireland 0 0 2 64 0 0 7 276
Microcredit: What can we learn from the past? 0 0 0 328 0 1 10 981
Microfinance and Famine: The Irish Loan Funds during the Great Famine 0 0 1 99 1 1 13 455
Newton's First Law as Applied to Pharmacies: Why Entry Order Matters for Generics 1 1 3 35 2 3 21 141
Patient income and health innovation 0 0 0 11 1 2 7 48
Predicting patent challenges for small-molecule drugs: A cross-sectional study 0 0 0 0 0 0 7 8
Preliminary Injunctions and Damage Rules in Patent Law 0 2 2 74 0 2 15 347
Price‐cap Regulation, Uncertainty and the Price Evolution of New Pharmaceuticals 0 0 0 9 0 0 8 43
Strategic Implications of Learning by Doing 0 0 0 87 0 0 9 570
Sustainable Financing of Innovative Therapies: A Review of Approaches 0 0 0 15 1 2 10 52
The Anti-Competitive Effects of Brand-Controlled "Pseudo- Generics" in the Canadian Pharmaceutical Market 0 0 0 233 0 0 13 743
The Role of Local Depositors in Controlling Expenses in Small‐Scale Financial Intermediation: An Empirical Analysis 0 0 0 16 0 0 9 93
The economic theory of cost‐effectiveness thresholds in health: Domestic and international implications 0 0 1 3 0 0 9 22
The impact of changing the reference countries on the list prices for patented medicines in Canada: A policy analysis 0 1 1 1 0 1 5 6
The importance of being first: evidence from Canadian generic pharmaceuticals 0 1 3 311 0 3 22 740
The large-scale integration of wind generation: Impacts on price, reliability and dispatchable conventional suppliers 0 0 1 61 1 1 18 181
The life-cycle of a microfinance institution: the Irish loan funds 0 0 0 157 0 1 9 468
The path of least resistance: Paying for antibiotics in non-human uses 0 0 0 6 0 0 8 41
Total Journal Articles 2 8 19 2,610 12 31 328 11,161


Statistics updated 2026-09-10